Story · Medicine & Biotech

J&J bets $2.2B on Ollin’s vision loss drug

2 outlets · first reported by BioPharma Dive on · latest · 2 hours of coverage

The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market. (BioPharma Dive)

Coverage, in order

  1. first BioPharma Dive indie
    J&J bets $2.2B on Ollin’s vision loss drug

    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

  2. MedCity News indie study randomized trial
    J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding

    Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offer advantages over Vabysmo, a Roche drug approved for wet age-related macular degeneration and diabetic macular edema.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.